Trophoblast cell-surface antigen 2 (Trop-2), a transmembrane glycoprotein, and Nectin-4, a cellular adhesion molecule abundant in urothelial carcinomas, are being explored as candidate predictive markers to investigate associations with risk stratification and response to antibody-drug conjugates (ADCs), e.g., sacituzumab govitecan and enfortumab vedotin, respectively [118]. Here, TACSTD2 is linked to urothelial carcinoma.